Rare Cancer Center

(NCCH) Akira Kawai, Yoshitaka Narita, Shigenobu Suzuki, Seiichi Yoshimoto, Kan Yonemori, Mayu Yunokawa, Emi Noguchi, Tsunori Shimoi, Yasushi Goto, Yoshitaka Honma, Chigusa Morizane, Motokiyo Komiyama, Tomoyasu Kato, Hirokazu Chuuman, Fumihiko Nakatani, Yoshikazu Tanzawa, Eisuke Kobayashi, Makoto Endo, Naoya Yamazaki, Arata Tsutsumida, Akira Takahashi, Kenjiro Namikawa, Wataru Munakata, Chitose Ogawa, Ayumu Arakawa, Miyuki Sone, Shunsuke Sugawara, Hiroshi Igaki, Kana Takahashi, Akihiko Yoshida, Noboru Yamamoto, Shunsuke Kondo, Koichi Ichimura, Tadashi Kondo, Takahiro Higashi, Takuro Sakurai, Makiko Murase, Yoko Katoh, Natumi Takeuti,

(NCCHE) Naoto Gotohda, Tetsuo Akimoto, Ako Hosono, Toshihiko Doi, Yoichi Naito, Junya Ueno

Introduction

The Rare Cancer Center was established in June 2014 as a multidisciplinary team to take measures against the innate problems associated with rare cancers. Based on discussions, rare cancers are defined as those with an incidence < 6/100,000/year. Although each subtype of rare cancer is rare by itself, they correspond to up to 15% of all new cases diagnosed as cancer when the numbers of each subtype of rare cancer are combined. Information on rare cancers has been scarce to date and this background makes it difficult for clinicians to diagnose rare cancers correctly and treat patients adequately. Another problem is a lack of experienced expertise in the field of rare cancers.

Our team and what we do

The Rare Cancer Center plays a central role in the treatment and management of rare cancers in the National Cancer Center (NCC).

The mission statements of the Rare Cancer Center are as follows.

1)Establishing a vital network for diagnosis and treatment for rare cancers in Japan.

2)Reviewing the problems associated with rare cancers in Japan, and taking up the issues and making proposals as medical professionals for rare cancers.

To enable the Rare Cancer Center to play its role, a total of 45 medical doctors, researchers, and nurses dealing with rare cancers have joined as members of the Rare Cancer Center. Each member of the Rare Cancer Center provides specialized and high-quality medical care to patients with rare cancers, and promotes researches for rare cancers by taking multidisciplinary approach.

Research activities

1.Staff Meeting

We had a bi-monthly conference to discuss the problems associated with rare cancers in each center (the NCC Hospital (NCCH) and the NCC Hospital East (NCCHE)). We also interact with adolescent and young adult (AYA) patients with rare cancers to share their experience and uncover their problems associated with rare cancers.

2.Establishment of website as a source to transmit information on rare cancers

We established a website of the Rare Cancer Center to transmit comprehensive, scientifically based, up-to-date unbiased information on rare cancers for patients and their families, and health professionals fighting against rare cancers (https://www.ncc.go.jp/jp/rcc/). We relaunched this website by adding information on seven rare cancers including sarcoma of the head and neck, neuroendocrine tumor, mesothelioma, peritoneal cancer, and lymphoma. We also added information on the endoscopic examination and treatment, and hematopoietic stem cell transplantation to the Diagnosis and Treatment section.

3.Establishment of the Rare Cancer Hotline

We established the Rare Cancer Hotline to provide consultation for patients with rare cancers and their families on the telephone. The number of consultations via the Rare Cancer Hotline was 5,416 cases in 2016 (Figure 1).

4.Sarcoma Conference

We are organizing a sarcoma group to diagnose and manage sarcoma patients in a multidisciplinary manner. We had a monthly "Sarcoma conference" and discussed the strategy of 45 sarcoma cases this year.

5.Researches for rare cancers

We are promoting researches for rare cancers. We especially promoted the researches highlighting the establishment of appropriate management of rare cancers from the aspect of medical policy. We also promoted basic researches for rare cancers and attempted to develop patient-derived tumor xenografts or cell lines in cooperation with the National Cancer Center Research Institute.

Education

We are making efforts to share information on rare cancers and enhance the development of human resources of rare cancers through conferences and seminars inside and outside the NCC.

Future prospects

The Rare Cancer Center plays a central role in all the aspects of medical care and researches for rare cancers in Japan. We should act as a leader to transmit comprehensive, scientifically based, up-to-date unbiased information on rare cancers for patients and their families, and health professionals, clarify how rare cancer care and research should be and work on the society regarding this information as well as to voluntarily perform medical care and research for rare cancers.

List of papers published in 2016

Journal

1.Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T, Yamaguchi K, Segawa Y, Omuro Y, Tamura T, Doi T, Yukisawa S, Yasui H, Nagashima F, Gotoh M, Esaki T, Emig M, Chandrawansa K, Liepa AM, Wilke H, Ichimiya Y, Ohtsu A. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer, 19:927-938, 2016

2.Ikeda K, Kojima M, Saito N, Sakuyama N, Koushi K, Watanabe T, Sugihara K, Akimoto T, Ito M, Ochiai A. Current status of the histopathological assessment, diagnosis, and reporting of colorectal neuroendocrine tumors: A Web survey from the Japanese Society for Cancer of Colon and Rectum. Pathol Int, 66:94-101, 2016

3.Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Okuyama H, Ueno H, Morizane C, Kondo S, Sakamoto Y, Okusaka T, Ochiai A. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer. Pancreas, 45:110-116, 2016

4.Saito Y, Kumamoto T, Makino Y, Tamai I, Ogawa C, Terakado H. A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors. Jpn J Clin Oncol, 46:856-861, 2016

5.Harano K, Yonemori K, Hirakawa A, Shimizu C, Katsumata N, Gemma A, Fujiwara Y, Tamura K. The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study. Breast Cancer, 23:797-806, 2016

6.Nokihara H, Yamada Y, Fujiwara Y, Yamamoto N, Wakui H, Nakamichi S, Kitazono S, Inoue K, Harada A, Taube T, Takeuchi Y, Tamura T. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors. Invest New Drugs, 34:66-74, 2016

7.Yasui N, Yoshida A, Kobayashi E, Nakatani F, Kawamoto H. Successful Treatment of Extra-Renal Noncerebral Rhabdoid Tumors with VIDE. Pediatr Blood Cancer, 63:352-354, 2016

8.Kurihara H, Shimizu C, Miyakita Y, Yoshida M, Hamada A, Kanayama Y, Yonemori K, Hashimoto J, Tani H, Kodaira M, Yunokawa M, Yamamoto H, Watanabe Y, Fujiwara Y, Tamura K. Molecular imaging using PET for breast cancer. Breast Cancer, 23:24-32, 2016

9.Hirokawa M, Sugitani I, Kakudo K, Sakamoto A, Higashiyama T, Sugino K, Toda K, Ogasawara S, Yoshimoto S, Hasegawa Y, Imai T, Onoda N, Orita Y, Kammori M, Fujimori K, Yamada H. Histopathological analysis of anaplastic thyroid carcinoma cases with long-term survival: A report from the Anaplastic Thyroid Carcinoma Research Consortium of Japan. Endocr J, 63:441-447, 2016

10.Sawada T, Watanabe M, Fujimura Y, Yagishita S, Shimoyama T, Maeda Y, Kanda S, Yunokawa M, Tamura K, Tamura T, Minami H, Koh Y, Koizumi F. Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells. Cancer Sci, 107:307-314, 2016

11.Matsumoto F, Ohba S, Fujimaki M, Ikeda K. The value of insulin-like growth factor-1 receptor for predicting early glottic carcinoma response to radiotherapy. Auris Nasus Larynx, 43:440-445, 2016

12.Shimomura A, Fujiwara Y, Kondo S, Kodaira M, Iwasa S, Kitano S, Tanabe Y, Tamura K, Yamamoto N. Tremelimumab-associated tumor regression following after initial progression: two case reports. Immunotherapy, 8:9-15, 2016

13.Kobayashi K, Matsumoto F, Kodaira M, Mori T, Murakami N, Yoshida A, Maki D, Teshima M, Fukasawa M, Itami J, Asai M, Yoshimoto S. Significance of delayed primary excision in localized nonmetastatic adult head and neck rhabdomyosarcoma. Cancer Med, 5:2708-2714, 2016

14.Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. Int J Clin Oncol, 21:168-176, 2016

15.Shoji H, Morizane C, Sakamoto Y, Kondo S, Ueno H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Ikeda M, Okusaka T. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. Jpn J Clin Oncol, 46:132-137, 2016

16.Takahashi S, Gotohda N, Kato Y, Konishi M. Measure of pancreas transection and postoperative pancreatic fistula. J Surg Res, 202:276-283, 2016

17.Ohura T, Higashi T, Ishizaki T, Nakayama T. Gaps between the subjective needs of older facility residents and how care workers understand them: a pairwise cross-sectional study. BMC Res Notes, 9:52, 2016

18.Nishida Y, Kato Y, Kudo M, Aizawa H, Okubo S, Takahashi D, Nakayama Y, Kitaguchi K, Gotohda N, Takahashi S, Konishi M. Preoperative Sarcopenia Strongly Influences the Risk of Postoperative Pancreatic Fistula Formation After Pancreaticoduodenectomy. J Gastrointest Surg, 20:1586-1594, 2016

19.Komai Y, Sugimoto M, Gotohda N, Matsubara N, Kobayashi T, Sakai Y, Shiga Y, Saito N. Patient-specific 3-dimensional Printed Kidney Designed for "4D" Surgical Navigation: A Novel Aid to Facilitate Minimally Invasive Off-clamp Partial Nephrectomy in Complex Tumor Cases. Urology, 91:226-233, 2016

20.Kato Y, Takahashi S, Gotohda N, Konishi M. The Likely Sites of Nodal Metastasis Differs According to the Tumor Extent in Distal Bile Duct Cancer. J Gastrointest Surg, 20:1618-1627, 2016

21.Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M, Kinoshita T, Ikeda M, Nakachi K, Yamazaki N, Mizuno S, Takayama T, Yamao K, Uesaka K, Furuse J, Endo I, Nakatsura T. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology, 5:e1129483, 2016

22.Yamashita M, Kitano S, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, Tamura K, Hamada A. A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells. Sci Rep, 6:19772, 2016

23.Tobinai K, Ogura M, Ishizawa K, Suzuki T, Munakata W, Uchida T, Aoki T, Morishita T, Ushijima Y, Takahara S. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. Int J Hematol, 103:86-94, 2016

24.Okuma HS, Kobayashi Y, Makita S, Kitahara H, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Tobinai K. Disseminated herpes zoster infection initially presenting with abdominal pain in patients with lymphoma undergoing conventional chemotherapy: A report of three cases. Oncol Lett, 12:809-814, 2016

25.Yamazaki N, Kiyohara Y, Kudoh S, Seki A, Fukuoka M. Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients. Int J Clin Oncol, 21:248-253, 2016

26.Kuboki Y, Yamashita S, Niwa T, Ushijima T, Nagatsuma A, Kuwata T, Yoshino T, Doi T, Ochiai A, Ohtsu A. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. Ann Oncol, 27:127-133, 2016

27.Ezawa I, Sawai Y, Kawase T, Okabe A, Tsutsumi S, Ichikawa H, Kobayashi Y, Tashiro F, Namiki H, Kondo T, Semba K, Aburatani H, Taya Y, Nakagama H, Ohki R. Novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells. Cancer Sci, 107:734-745, 2016

28.Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature, 534:402-406, 2016

29.Asano Y, Kawase T, Okabe A, Tsutsumi S, Ichikawa H, Tatebe S, Kitabayashi I, Tashiro F, Namiki H, Kondo T, Semba K, Aburatani H, Taya Y, Nakagama H, Ohki R. IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis. Sci Rep, 6:19174, 2016

30.Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors. Oncologist, 21:156-164, 2016

31.Fukushima R, Kobayashi Y, Fukuhara S, Miyamoto Ki, Munakata W, Maruyama D, Kim S-W, Watanabe T, Taniguchi H, Maeshima A, Tobinai K. A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma. J Chemother, 28:116-122, 2016

32.Yachida S, Wood LD, Suzuki M, Takai E, Totoki Y, Kato M, Luchini C, Arai Y, Nakamura H, Hama N, Elzawahry A, Hosoda F, Shirota T, Morimoto N, Hori K, Funazaki J, Tanaka H, Morizane C, Okusaka T, Nara S, Shimada K, Hiraoka N, Taniguchi H, Higuchi R, Oshima M, Okano K, Hirono S, Mizuma M, Arihiro K, Yamamoto M, Unno M, Yamaue H, Weiss MJ, Wolfgang CL, Furukawa T, Nakagama H, Vogelstein B, Kiyono T, Hruban RH, Shibata T. Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. Cancer Cell, 29:229-240, 2016

33.Hirahata M, Osaki M, Kanda Y, Sugimoto Y, Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Kawai A, Ito H, Ochiya T, Okada F. PAI-1, a target gene of miR-143, regulates invasion and metastasis by upregulating MMP-13 expression of human osteosarcoma. Cancer Med, 5:892-902, 2016

34.Takahashi N, Furuta K, Taniguchi H, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y, Yamada Y. Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer. Oncotarget, 7:4925-4938, 2016

35.Ohara Y, Ohto H, Tasaki T, Sano H, Mochizuki K, Akaihata M, Kobayashi S, Waragai T, Ito M, Hosoya M, Nollet KE, Ikeda K, Ogawa C, Kanno T, Shikama Y, Kikuta A. Comprehensive technical and patient-care optimization in the management of pediatric apheresis for peripheral blood stem cell harvesting. Transfus Apher Sci, 55:338-343, 2016

36.Umemura K, Iwaki T, Kimura T, Ogawa C, Fukuda T, Taniguchi S, Horibe K, Goto H, Yoshimura K, Watanabe Y, Nitani C, Kikuta A. Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects. Clin Pharmacol Drug Dev, 5:548-551, 2016

37.Nagata Y, Kontani K, Enami T, Kataoka K, Ishii R, Totoki Y, Kataoka TR, Hirata M, Aoki K, Nakano K, Kitanaka A, Sakata-Yanagimoto M, Egami S, Shiraishi Y, Chiba K, Tanaka H, Shiozawa Y, Yoshizato T, Suzuki H, Kon A, Yoshida K, Sato Y, Sato-Otsubo A, Sanada M, Munakata W, Nakamura H, Hama N, Miyano S, Nureki O, Shibata T, Haga H, Shimoda K, Katada T, Chiba S, Watanabe T, Ogawa S. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood, 127:596-604, 2016

38.Yoshihara H, Kamiya T, Hosoya Y, Hasegawa D, Ogawa C, Asanuma H, Mizuno R, Hosoya R, Manabe A. Ewing sarcoma/primitive neuroectodermal tumor of the kidney treated with chemotherapy including ifosfamide. Pediatr Int, 58:766-769, 2016

39.Ohmoto A, Yachida S, Kubo E, Takai E, Suzuki M, Shimada K, Okusaka T, Morizane C. Clinicopathologic Features and Germline Sequence Variants in Young Patients (≤40 Years Old) With Pancreatic Ductal Adenocarcinoma. Pancreas, 45:1056-1061, 2016

40.Koh K, Ogawa C, Okamoto Y, Kudo K, Inagaki J, Morimoto T, Mizukami H, Ecstein-Fraisse E, Kikuta A. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan. Int J Hematol, 104:245-255, 2016

41.Mizusawa J, Morizane C, Okusaka T, Katayama H, Ishii H, Fukuda H, Furuse J. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Jpn J Clin Oncol, 46:385-388, 2016

42.Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, Kunitoh H, Matsumoto S, Takano A, Shimizu K, Goto A, Tsuta K, Watanabe S, Ohe Y, Watanabe Y, Goto Y, Nokihara H, Furuta K, Yoshida A, Goto K, Hishida T, Tsuboi M, Tsuchihara K, Miyagi Y, Nakayama H, Yokose T, Tanaka K, Nagashima T, Ohtaki Y, Maeda D, Imai K, Minamiya Y, Sakamoto H, Saito A, Shimada Y, Sunami K, Saito M, Inazawa J, Nakamura Y, Yoshida T, Yokota J, Matsuda F, Matsuo K, Daigo Y, Kubo M, Kohno T. Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma. Nat Commun, 7:12451, 2016

43.Ophthalmic Oncology Task Force (Gallie BL, Simpson ER, Saakyan S, Amiryan A, Valskiy V, Finger PT, Chin KJ, Semenova E, Seregard S, Fili M, Wilson M, Haik B, Caminal JM, Català J, Gutierrez C, Pelayes DE, Folgar AM, Jager MJ, Dogrusöz M, Luyten GP, Singh A, Schachat AP, Suzuki S, Aihara Y).Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma. Ophthalmology, 123:86-91, 2016

44.Tsushima T, Mizusawa J, Sudo K, Honma Y, Kato K, Igaki H, Tsubosa Y, Shinoda M, Nakamura K, Fukuda H, Kitagawa Y. Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303. Medicine (Baltimore), 95:e3699, 2016

45.Kudo M, Yamamoto Y, Koga Y, Hamaguchi T, Akimoto T, Yasunaga M, Matsumura Y. Effect of combined treatment with micelle-incorporated cisplatin (NC-6004) and S-1 on human gastric cancer xenografts. Mol Clin Oncol, 5:817-822, 2016

46.Kondo T. Proteogenomics for the Study of Gastrointestinal Stromal Tumors. Adv Exp Med Biol, 926:139-151, 2016

47.Morofuji N, Ojima H, Hiraoka N, Okusaka T, Esaki M, Nara S, Shimada K, Kishi Y, Kondo T. Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma. Clin Proteomics, 13:28, 2016

48.Miyoshi Y, Yorifuji T, Horikawa R, Takahashi I, Nagasaki K, Ishiguro H, Fujiwara I, Ito J, Oba M, Kawamoto H, Fujisaki H, Kato M, Shimizu C, Kato T, Matsumoto K, Sago H, Takimoto T, Okada H, Suzuki N, Yokoya S, Ogata T, Ozono K. Gonadal function, fertility, and reproductive medicine in childhood and adolescent cancer patients: a national survey of Japanese pediatric endocrinologists. Clin Pediatr Endocrinol, 25:45-57, 2016

49.Yamasaki H, Miyamoto M, Yamamoto Y, Kondo T, Watanabe T, Ohta T. Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor. Genes Cells, 21:852-860, 2016

50.Pan X, Yoshida A, Kawai A, Kondo T. Current status of publicly available sarcoma cell lines for use in proteomic studies. Expert Rev Proteomics, 13:227-240, 2016

51.Araki N, Takahashi S, Sugiura H, Ueda T, Yonemoto T, Takahashi M, Morioka H, Hiraga H, Hiruma T, Kunisada T, Matsumine A, Kawai A. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy. Eur J Cancer, 56:122-130, 2016

52.Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun, 4:79, 2016

53.Fujiki M, Miyamoto S, Kobayashi E, Sakuraba M, Chuman H. Early detection of local recurrence after soft tissue sarcoma resection and flap reconstruction. Int Orthop, 40:1975-1980, 2016

54.Gobara H, Arai Y, Kobayashi T, Yamakado K, Inaba Y, Kodama Y, Yamagami T, Sone M, Watanabe H, Okumura Y, Shinya T, Kurihara H, Kanazawa S. Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702). Jpn J Radiol, 34:556-563, 2016

55.Hanakita S, Shin M, Koga T, Igaki H, Saito N. Risk Reduction of Cerebral Stroke After Stereotactic Radiosurgery for Small Unruptured Brain Arteriovenous Malformations. Stroke, 47:1247-1252, 2016

56.Hanakita S, Shin M, Koga T, Igaki H, Saito N. Outcomes of volume-staged radiosurgery for cerebral arteriovenous malformations larger than 20 cm3 with more than 3 years of follow-up. World Neurosurg, 87:242-249, 2016

57.Hirano Y, Nakamura N, Zenda S, Hojo H, Motegi A, Arahira S, Toshima M, Onozawa M, Akimoto T. Incidence and severity of adverse events associated with re-irradiation for spine or pelvic bone metastases. Int J Clin Oncol, 21:609-614, 2016

58.Horie M, Tamiya H, Goto Y, Suzuki M, Matsuzaki H, Hasegawa WT, Noguchi S, Kawakami M, Matsuta K, Nagase T, Sakamoto Y. Nonspecific elevation of serum Aspergillus galactomannan antigen levels in patients with rheumatoid arthritis. Respir Investig, 54:44-49, 2016

59.Iizuka J, Hashimoto Y, Hashimoto Y, Kondo T, Takagi T, Nozaki T, Shimizu T, Akimoto T, Ishida H, Karasawa K, Tanabe K. Efficacy and Feasibility of Low-Dose Rate Brachytherapy for Prostate Cancer in Renal Transplant Recipients. Transplant Proc, 48:910-913, 2016

60.Iizuka J, Hashimoto Y, Hashimoto Y, Kondo T, Takagi T, Nozaki T, Shimizu T, Akimoto T, Ishida H, Karasawa K, Tanabe K. Efficacy and Feasibility of Intensity-Modulated Radiation Therapy for Prostate Cancer in Renal Transplant Recipients. Transplant Proc, 48:914-917, 2016

61.Araki T, Takashima A, Hamaguchi T, Honma Y, Iwasa S, Okita N, Kato K, Yamada Y, Hashimoto H, Taniguchi H, Kushima R, Nakao K, Boku N, Shimada Y. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract. Anticancer Drugs, 27:794-799, 2016

62.Imamura T, Kiyokawa N, Kato M, Imai C, Okamoto Y, Yano M, Ohki K, Yamashita Y, Kodama Y, Saito A, Mori M, Ishimaru S, Deguchi T, Hashii Y, Shimomura Y, Hori T, Kato K, Goto H, Ogawa C, Koh K, Taki T, Manabe A, Sato A, Kikuta A, Adachi S, Horibe K, Ohara A, Watanabe A, Kawano Y, Ishii E, Shimada H. Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan. Blood Cancer J, 6:e419, 2016

63.Inaba K, Okamoto H, Wakita A, Tsuchida K, Kashihara T, Kobayashi K, Harada K, Kitaguchi M, Sekii S, Umezawa R, Takahashi K, Murakami N, Ito Y, Igaki H, Uno T, Itami J. Long-term observations of radiation-induced creatinine clearance reduction and renal parenchymal volume atrophy. Radiother Oncol, 120:145-149, 2016

64.Bun S, Yunokawa M, Ebata T, Shimomura A, Shimoi T, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Makino Y, Hayashi Y, Tamura K. Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol, 78:745-752, 2016

65.Ito T, Matsubara D, Tanaka I, Makiya K, Tanei Z, Kumagai Y, Shiu SJ, Nakaoka HJ, Ishikawa S, Isagawa T, Morikawa T, Shinozaki-Ushiku A, Goto Y, Nakano T, Tsuchiya T, Tsubochi H, Komura D, Aburatani H, Dobashi Y, Nakajima J, Endo S, Fukayama M, Sekido Y, Niki T, Murakami Y. Loss of YAP1 defines neuroendocrine differentiation of lung tumors. Cancer Sci, 107:1527-1538, 2016

66.Ebata T, Yunokawa M, Bun S, Shimomura A, Shimoi T, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K. Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas. Cancer Chemother Pharmacol, 78:1283-1288, 2016

67.Iwata S, Uehara K, Ogura K, Akiyama T, Shinoda Y, Yonemoto T, Kawai A. Reliability and Validity of a Japanese-language and Culturally Adapted Version of the Musculoskeletal Tumor Society Scoring System for the Lower Extremity. Clin Orthop Relat Res, 474:2044-2052, 2016

68.Maeshima AM, Taniguchi H, Toyoda K, Yamauchi N, Makita S, Fukuhara S, Munakata W, Maruyama D, Kobayashi Y, Tobinai K. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. Br J Haematol, 174:923-931, 2016

69.Kato I, Yoshida A, Ikegami M, Okuma T, Tonooka A, Horiguchi S, Funata N, Kawai A, Goto T, Hishima T, Aoki I, Motoi T. FOSL1 immunohistochemistry clarifies the distinction between desmoplastic fibroblastoma and fibroma of tendon sheath. Histopathology, 69:1012-1020, 2016

70.Fujiwara Y, Hamada A, Mizugaki H, Aikawa H, Hata T, Horinouchi H, Kanda S, Goto Y, Itahashi K, Nokihara H, Yamamoto N, Ohe Y. Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism. Cancer Sci, 107:1117-1123, 2016

71.Kawai A, Araki N, Hiraga H, Sugiura H, Matsumine A, Ozaki T, Ueda T, Ishii T, Esaki T, Machida M, Fukasawa N. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup. Jpn J Clin Oncol, 46:248-253, 2016

72.Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK, Mori J, Asou H, Chan EM, Yamamoto N. Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemother Pharmacol, 78:281-288, 2016

73.Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Miwa S, Tsuchiya H. Clinical Outcome of Reconstruction Using Frozen Autograft for a Humeral Bone Tumor. Anticancer Res, 36:6631-6635, 2016

74.Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group. Gynecol Oncol, 141:447-453, 2016

75.Hatogai K, Kitano S, Fujii S, Kojima T, Daiko H, Nomura S, Yoshino T, Ohtsu A, Takiguchi Y, Doi T, Ochiai A. Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma. Oncotarget, 7:47252-47264, 2016

76.Makita S, Maruyama D, Maeshima AM, Taniguchi H, Miyamoto K, Kitahara H, Fukuhara S, Munakata W, Kobayashi Y, Itami J, Tobinai K. Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. Int J Hematol, 104:236-244, 2016

77.Kobayashi K, Kurihara H, Watanabe Y, Murakami N, Inaba K, Nakamura S, Wakita A, Okamoto H, Umezawa R, Takahashi K, Igaki H, Ito Y, Yoshimoto S, Shigematsu N, Itami J. In vivo spatial correlation between 18F-BPA and 18F-FDG uptakes in head and neck cancer. Appl Radiat Isot, 115:138-146, 2016

78.Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Tamura T, Ohe Y. Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity. Int J Radiat Oncol Biol Phys, 94:155-162, 2016

79.Makita S, Maeshima AM, Taniguchi H, Kitahara H, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Kobayashi Y, Tobinai K. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma. Int J Hematol, 104:396-399, 2016

80.Tongdee E, Touloei K, Shitabata PK, Shareef S, Maranda EL. Keloidal Atypical Fibroxanthoma: Case and Review of the Literature. Case Rep Dermatol, 8:156-163, 2016

81.Kohno R, Yamaguchi H, Motegi K, Hotta K, Nishioka S, Akimoto T. In vivo dosimetry of an anthropomorphic phantom using the RADPOS for proton beam therapy. Int J Med Phys Clin Eng Radiat Oncol, 5:177-183, 2016

82.Kanda S, Goto K, Shiraishi H, Kubo E, Tanaka A, Utsumi H, Sunami K, Kitazono S, Mizugaki H, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Hozumi H, Tamura T. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Ann Oncol, 27:2242-2250, 2016

83.Miyamoto K, Kobayashi Y, Maeshima AM, Taniguchi H, Nomoto J, Kitahara H, Fukuhara S, Munakata W, Maruyama D, Tobinai K. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Int J Hematol, 103:693-702, 2016

84.Komori K, Yanagisawa R, Miyairi Y, Sakashita K, Shiohara M, Fujihara I, Morita D, Nakamura T, Ogiso Y, Sano K, Shirahata M, Fukuoka K, Ichimura K, Shigeta H. Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression. Pediatr Blood Cancer, 63:152-155, 2016

85.Tamura A, Kato K, Suzuki M, Sone M, Tanaka R, Nakasato T, Ehara S. CT-Guided Percutaneous Radiologic Gastrostomy for Patients with Head and Neck Cancer: A Retrospective Evaluation in 177 Patients. Cardiovasc Intervent Radiol, 39:271-278, 2016

86.Katsuya Y, Horinouchi H, Asao T, Kitahara S, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Watanabe S, Tsuta K, Ohe Y. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer, 99:4-10, 2016

87.Kyo S, Kato T, Nakayama K. Current concepts and practical techniques of nerve-sparing laparoscopic radical hysterectomy. Eur J Obstet Gynecol Reprod Biol, 207:80-88, 2016

88.Kim Y, Kobayashi E, Kubota D, Suehara Y, Mukaihara K, Akaike K, Ito A, Kaneko K, Chuman H, Kawai A, Kitano S. Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance. Oncotarget, 7:70832-70844, 2016

89.Maeda E, Higashi T, Hasegawa T, Yokoya S, Mochizuki T, Ishii T, Ito J, Kanzaki S, Shimatsu A, Takano K, Tajima T, Tanaka H, Tanahashi Y, Teramoto A, Nagai T, Hanew K, Horikawa R, Yorifuji T, Wada N, Tanaka T. Effects of financial support on treatment of adolescents with growth hormone deficiency: a retrospective study in Japan. BMC Health Serv Res, 16:602, 2016

90.Kimbara S, Kondo S. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol, 22:7440-7452, 2016

91.Mitsuya K, Nakasu Y, Narita Y, Nakasu S, Ohno M, Miyakita Y, Abe M, Ito I, Hayashi N, Endo M. Comet tail sign: A pitfall of post-gadolinium magnetic resonance imaging findings for metastatic brain tumors. J Neurooncol, 127:589-595, 2016

92.Mimura H, Arai Y, Yamakado K, Sone M, Takeuchi Y, Miki T, Gobara H, Sakuhara Y, Yamamoto T, Sato Y, Kanazawa S. Phase I/II Study of Radiofrequency Ablation for Malignant Renal Tumors: Japan Interventional Radiology in Oncology Study Group 0701. Cardiovasc Intervent Radiol, 39:717-723, 2016

93.Makino Y, Watanabe M, Makihara RA, Nokihara H, Yamamoto N, Ohe Y, Sugiyama E, Sato H, Hayashi Y. Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients. Asia Pac J Clin Oncol, 12:259-264, 2016

94.Miyamoto S, Arikawa M, Fujiki M, Kawai A, Kobayashi E, Sakuraba M. The Superior Rectal Artery as a Recipient Vessel for Free Flap Transfer After Partial Sacrectomy in Patients With Chordoma. Ann Plast Surg, 76:315-317, 2016

95.Yuda S, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto K, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y, Tajima K, Taniguchi H, Tobinai K. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era. Ann Hematol, 95:2017-2022, 2016

96.Matsuo K, Takazawa Y, Ross MS, Elishaev E, Podzielinski I, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Matsuzaki S, Baba T, Satoh S, Shida M, Nishikawa T, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Fujiwara K, Hazama Y, Kadogami D, Moffitt MN, Takeuchi S, Nishimura M, Iwasaki K, Ushioda N, Johnson MS, Yoshida M, Hakam A, Li SW, Richmond AM, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Yamaguchi K, Oishi T, Kajiwara H, Hasegawa K, Yasuda M, Kawana K, Suda K, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Wakatsuki A, Sugiyama T, Pejovic T, Nagano T, Shimoya K, Andoh M, Shiki Y, Enomoto T, Sasaki T, Mikami M, Shimada M, Konishi I, Kimura T, Post MD, Shahzad MM, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann Oncol, 27:1257-1266, 2016

97.Kawajiri A, Maruyama D, Maeshima AM, Nomoto J, Makita S, Kitahara H, Miyamoto KI, Fukuhara S, Suzuki T, Munakata W, Tajima K, Itami J, Taniguchi H, Kobayashi Y, Tobinai K. Impact of the double expression of MYC and BCL2 on outcomes of localized primary gastric diffuse large B-cell lymphoma patients in the rituximab era. Blood Cancer J, 6:e477, 2016

98.Miyamoto S, Fujiki M, Sakisaka M, Kawai A. Combined Use of the Latissimus Dorsi Musculocutaneous Flap and the Anterolateral Thigh Flap to Reconstruct an Extensive Shoulder Defect in an NF-1 Patient. Plast Reconstr Surg Glob Open, 4:e670, 2016

99.Munakata W, Tobinai K. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma. Expert Opin Drug Discov, 11:1123-1130, 2016

100.Miyamoto S, Fujiki M, Setsu N, Kawai A. Simultaneous reconstruction of the bone and vessels for complex femoral defect. World J Surg Oncol, 14:291, 2016

101.Miyamoto S, Kagaya Y, Arikawa M, Kobayashi E. Combined Use of an Anterolateral Thigh Flap and Superficial Inferior Epigastric Artery Flap for Reconstruction of an Extensive Abdominal Wall Defect. Plast Reconstr Surg Glob Open, 4:e1121, 2016

102.Asao T, Fujiwara Y, Sunami K, Kitahara S, Goto Y, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Ichikawa H, Kohno T, Tsuta K, Watanabe S, Takahashi K, Ohe Y. Medical treatment involving investigational drugs and genetic profile of thymic carcinoma. Lung Cancer, 93:77-81, 2016

103.Mizugaki H, Yamamoto N, Murakami H, Kenmotsu H, Fujiwara Y, Ishida Y, Kawakami T, Takahashi T. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Invest New Drugs, 34:596-603, 2016

104.Miyazaki M, Arai Y, Myoui A, Gobara H, Sone M, Rosenthal DI, Tsushima Y, Kanazawa S, Ehara S, Endo K. Phase I/II Multi-Institutional Study of Percutaneous Radiofrequency Ablation for Painful Osteoid Osteoma (JIVROSG-0704). Cardiovasc Intervent Radiol, 39:1464-1470, 2016

105.Nakamura Y, Kitano S, Takahashi A, Tsutsumida A, Namikawa K, Tanese K, Abe T, Funakoshi T, Yamamoto N, Amagai M, Yamazaki N. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget, 7:77404-77415, 2016

106.Mizumoto M, Murayama S, Akimoto T, Demizu Y, Fukushima T, Ishida Y, Oshiro Y, Numajiri H, Fuji H, Okumura T, Shirato H, Sakurai H. Proton beam therapy for pediatric malignancies: a retrospective observational multicenter study in Japan. Cancer Med, 5:1519-1525, 2016

107.Nokihara H, Yamamoto N, Ohe Y, Hiraoka M, Tamura T. Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-small Cell Lung Cancer. Clin Ther, 38:338-347, 2016

108.Mizutani S, Takada Y, Kohno R, Hotta K, Tansho R, Akimoto T. Application of dose kernel calculation using a simplified Monte Carlo method to treatment plan for scanned proton beams. J Appl Clin Med Phys, 17:5747, 2016

109.Sasaki Y, Hamaguchi T, Yamada Y, Takahashi N, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Nagai Y, Taniguchi H, Boku N, Ushijima T, Shimada Y. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis. Asian Pac J Cancer Prev, 17:539-543, 2016

110.Mori T, Nakayama R, Endo M, Hiraga H, Tomita M, Fukase N, Kobayashi E, Kawai A, Ueda T, Morioka H. Forty-eight cases of leiomyosarcoma of bone in Japan: A multicenter study from the Japanese musculoskeletal oncology group. J Surg Oncol, 114:495-500, 2016

111.Miyamoto S, Fujiki M, Kawai A, Chuman H, Sakuraba M. Anterolateral thigh flap for axillary reconstruction after sarcoma resection. Microsurgery, 36:378-383, 2016

112.Morioka H, Takahashi S, Araki N, Sugiura H, Ueda T, Takahashi M, Yonemoto T, Hiraga H, Hiruma T, Kunisada T, Matsumine A, Susa M, Nakayama R, Nishimoto K, Kikuta K, Horiuchi K, Kawai A. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. BMC Cancer, 16:479, 2016

113.Yoshida A, Goto K, Kodaira M, Kobayashi E, Kawamoto H, Mori T, Yoshimoto S, Endo O, Kodama N, Kushima R, Hiraoka N, Motoi T, Kawai A. CIC-rearranged Sarcomas: A Study of 20 Cases and Comparisons With Ewing Sarcomas. Am J Surg Pathol, 40:313-323, 2016

114.Mukaihara K, Suehara Y, Kohsaka S, Kubota D, Toda-Ishii M, Akaike K, Fujimura T, Kobayashi E, Yao T, Ladanyi M, Kaneko K, Saito T. Expression of F-actin-capping protein subunit beta, CAPZB, is associated with cell growth and motility in epithelioid sarcoma. BMC Cancer, 16:206, 2016

115.Ichimura K, Fukushima S, Totoki Y, Matsushita Y, Otsuka A, Tomiyama A, Niwa T, Takami H, Nakamura T, Suzuki T, Fukuoka K, Yanagisawa T, Mishima K, Nakazato Y, Hosoda F, Narita Y, Shibui S, Yoshida A, Mukasa A, Saito N, Kumabe T, Kanamori M, Tominaga T, Kobayashi K, Shimizu S, Nagane M, Iuchi T, Mizoguchi M, Yoshimoto K, Tamura K, Maehara T, Sugiyama K, Nakada M, Sakai K, Kanemura Y, Nonaka M, Asai A, Yokogami K, Takeshima H, Kawahara N, Takayama T, Yao M, Kato M, Nakamura H, Hama N, Sakai R, Ushijima T, Matsutani M, Shibata T, Nishikawa R. Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy. Acta Neuropathol, 131:889-901, 2016

116.Okuma HS, Koizumi F, Hirakawa A, Nakatochi M, Komori O, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies. Br J Cancer, 115:411-419, 2016

117.Murakami N, Kato T, Miyamoto Y, Nakamura S, Wakita A, Okamoto H, Tsuchida K, Kashihara T, Kobayashi K, Harada K, Kitaguchi M, Sekii S, Takahashi K, Umezawa R, Inaba K, Ito Y, Igaki H, Itami J. Salvage High-dose-rate Interstitial Brachytherapy for Pelvic Recurrent Cervical Carcinoma After Hysterectomy. Anticancer Res, 36:2413-2421, 2016

118.Okuma HS, Kondo S. Trends in the development of MET inhibitors for hepatocellular carcinoma. Future Oncol, 12:1275-1286, 2016

119.Murakami N, Kobayashi K, Kato T, Nakamura S, Wakita A, Okamoto H, Shima S, Tsuchida K, Kashihara T, Harada K, Takahashi K, Umezawa R, Inaba K, Ito Y, Igaki H, Itami J. The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer. J Contemp Brachytherapy, 8:391-398, 2016

120.Sasada S, Kodaira M, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Ifosfamide and Etoposide Chemotherapy in the Treatment of Recurrent/Refractory Rhabdomyosarcoma in Adults. Anticancer Res, 36:2429-2432, 2016

121.Murakami N, Matsumoto F, Yoshimoto S, Ito Y, Mori T, Ueno T, Tuchida K, Kashihara T, Kobayashi K, Harada K, Kitaguchi M, Sekii S, Umezawa R, Takahashi K, Inaba K, Igaki H, Itami J. Patterns of recurrence after selective postoperative radiation therapy for patients with head and neck squamous cell carcinoma. BMC Cancer, 16:192, 2016

122.Satake H, Tahara M, Mochizuki S, Kato K, Hara H, Yokota T, Kiyota N, Kii T, Chin K, Zenda S, Kojima T, Bando H, Yamazaki T, Iwasa S, Honma Y, Hamauchi S, Tsushima T, Ohtsu A. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol, 78:91-99, 2016

123.Murakami N, Norihisa Y, Isohashi F, Murofushi K, Ariga T, Kato T, Inaba K, Okamoto H, Ito Y, Toita T, Itami J. Proposed definition of the vaginal cuff and paracolpium clinical target volume in postoperative uterine cervical cancer. Pract Radiat Oncol, 6:5-11, 2016

124.Setsu N, Kobayashi E, Asano N, Yasui N, Kawamoto H, Kawai A, Horiuchi K. Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab, 34:118-122, 2016

125.Shiba S, Morizane C, Hiraoka N, Sasaki M, Koga F, Sakamoto Y, Kondo S, Ueno H, Ikeda M, Yamada T, Shimada K, Kosuge T, Okusaka T. Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. w, 16:99-105, 2016

126.Nakamura N, Takahashi O, Zenda S, Kawamori J, Ogita M, Onozawa M, Arahira S, Toshima M, Motegi A, Hirano Y, Hojo H, Akimoto T. Neuropathic Pain Features in Patients with Bone Metastases. Clin Oncol (R Coll Radiol), 28:204-208, 2016

127.Ito J, Asano N, Kawai A, Yoshida A. The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas: a validation study. Hum Pathol, 47:32-37, 2016

128.Nakamura S, Murakami N, Inaba K, Wakita A, Kobayashi K, Takahashi K, Okamoto H, Umezawa R, Morota M, Sumi M, Igaki H, Ito Y, Itami J. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer. BMC Cancer, 16:296, 2016

129.Akiyama T, Saita K, Ogura K, Kawai A, Imanishi J, Yazawa Y, Kawashima N, Ogata T. The effect of an external hip joint stabiliser on gait function after surgery for tumours located around the circumference of the pelvis: analysis of seven cases of internal hemipelvectomy or proximal femur resection. Int Orthop, 40:561-567, 2016

130.Ohno M, Narita Y, Miyakita Y, Matsushita Y, Arita H, Yonezawa M, Yoshida A, Fukushima S, Takami H, Ichimura K, Shibui S. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome. Jpn J Clin Oncol, 46:31-39, 2016

131.Nakamura T, Matsumine A, Kawai A, Araki N, Goto T, Yonemoto T, Sugiura H, Nishida Y, Hiraga H, Honoki K, Yasuda T, Boku S, Sudo A, Ueda T. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer, 122:1408-1416, 2016

132.Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients. Cancer Immunol Res, 4:592-599, 2016

133.Ohno M, Narita Y, Miyakita Y, Shibui S. The necessity of long-term follow-up including spinal examination after successful initial treatment of intracranial germinoma: case reports. Childs Nerv Syst, 32:547-551, 2016

134.Takahashi N, Iwasa S, Fukahori M, Sudo K, Sasaki Y, Shoji H, Honma Y, Okita NT, Takashima A, Hamaguchi T, Boku N, Shimada Y, Honda K, Yamada T, Yamada Y. A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab. Cancer Chemother Pharmacol, 78:567-575, 2016

135.Ogasawara S, Fujii Y, Kaneko MK, Oki H, Sabit H, Nakada M, Suzuki H, Ichimura K, Komori T, Kato Y. Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6. Monoclon Antib Immunodiagn Immunother, 35:254-258, 2016

136.Takahashi N, Iwasa S, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita NT, Kato K, Hamaguchi T, Yamada Y. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol, 142:1727-1738, 2016

137.Ogata D, Yanagisawa H, Suzuki K, Oashi K, Yamazaki N, Tsuchida T. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma. Med Oncol, 33:116, 2016

138.Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H, Kubo A, Shuto T, Ohno M, Miyakita Y, Kocialkowski S, Sasayama T, Hashimoto N, Maehara T, Shibui S, Ushijima T, Kawahara N, Narita Y, Ichimura K. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol, 42:279-290, 2016

139.Takahashi N, Iwasa S, Taniguchi H, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Hamaguchi T, Shimada Y, Yamada Y. Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies. Br J Cancer, 114:1003-1011, 2016

140.Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, Soda M, Ueda H, Yasuda T, Yamaguchi H, Lee J, Shishido-Hara Y, Sasaki A, Shirahata M, Mishima K, Ichimura K, Mukasa A, Narita Y, Saito N, Aburatani H, Nishikawa R, Nagane M, Mano H. Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol, 131:865-875, 2016

141.Tamura K, Hashimoto J, Tanabe Y, Kodaira M, Yonemori K, Seto T, Hirai F, Arita S, Toyokawa G, Chen L, Yamamoto H, Kawata T, Lindemann J, Esaki T. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol, 77:787-795, 2016

142.Okamoto H, Hamada M, Sakamoto E, Wakita A, Nakamura S, Kato T, Abe Y, Takahashi K, Igaki H, Itami J. Log-file analysis of accuracy of beam localization for brain tumor treatment by CyberKnife. Pract Radiat Oncol, 6:e361-e367, 2016

143.Tamura K, Mukai H, Naito Y, Yonemori K, Kodaira M, Tanabe Y, Yamamoto N, Osera S, Sasaki M, Mori Y, Hashigaki S, Nagasawa T, Umeyama Y, Yoshino T. Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. Cancer Sci, 107:755-763, 2016

144.Okita Y, Narita Y, Miyakita Y, Miyahara R, Ohno M, Takahashi M, Nonaka M, Kanemura Y, Nakajima S, Fujinaka T. Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy. Mol Clin Oncol, 5:179-185, 2016

145.Tamura Y, Nokihara H, Honda K, Tanabe Y, Asahina H, Yamada Y, Enatsu S, Kurek R, Yamamoto N, Tamura T. Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol, 78:995-1002, 2016

146.Doi T, Lee K-H, Kim T-M, Ohtsu A, Kim TY, Ikeda M, Yoh K, Gallo Stampino C, Hirohashi T, Suzuki A, Fujii Y, Andrew Williams J, Bang Y-J. A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors. Cancer Med, 5:1454-1463, 2016

147.Tanabe Y, Ichikawa H, Kohno T, Yoshida H, Kubo T, Kato M, Iwasa S, Ochiai A, Yamamoto N, Fujiwara Y, Tamura K. Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. Mol Cancer, 15:73, 2016

148.Doi T, Shitara K, Kojima T, Yoshino T, Dontabhaktuni A, Rebscher H, Tang S, Cosaert J, Ohtsu A. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol, 77:1253-1262, 2016

149.Nezu Y, Hagiwara K, Yamamoto Y, Fujiwara T, Matsuo K, Yoshida A, Kawai A, Saito T, Ochiya T. miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. Oncogene, 35:6177-6188, 2016

150.Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents. Oncologist, 21:508-513, 2016

151.Yoh K, Doi T, Ohmatsu H, Kojima T, Takahashi H, Zenke Y, Wacheck V, Enatsu S, Nakamura T, Turner K, Uenaka K. A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies. Invest New Drugs, 34:584-595, 2016

152.Ooishi M, Motegi A, Kawashima M, Arahira S, Zenda S, Nakamura N, Ariji T, Tokumaru S, Sakuraba M, Tahara M, Hayashi R, Akimoto T. Patterns of failure after postoperative intensity-modulated radiotherapy for locally advanced and recurrent head and neck cancer. Jpn J Clin Oncol, 46:919-927, 2016

153.Osuga K, Nakajima Y, Sone M, Arai Y, Nambu Y, Hori S. Transarterial embolization of hypervascular tumors using trisacryl gelatin microspheres (Embosphere): a prospective multicenter clinical trial in Japan. Jpn J Radiol, 34:366-375, 2016

154.Yamaguchi T, Iwasa S, Nagashima K, Ikezawa N, Hamaguchi T, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Yamada Y, Shimada Y. Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer. Anticancer Res, 36:3531-3536, 2016

155.Nagatani Y, Shitara K, Bando H, Kuboki Y, Okamoto W, Kojima T, Yoshino T, Nishida T, Ohtsu A, Doi T. Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials. BMC Cancer, 16:889, 2016

156.Bando H, Doi T, Muro K, Yasui H, Nishina T, Yamaguchi K, Takahashi S, Nomura S, Kuno H, Shitara K, Sato A, Ohtsu A. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). Eur J Cancer, 62:46-53, 2016

157.Doi A, Sumiyoshi T, Omori Y, Oyamada Y, Kumano K, Yoshizaki N, Hirayama M, Suzuki Y, Okushiba S, Kogawa T, Doi T, Kondo H. Double Extramedullary Plasmacytoma of the Stomach with a Long-term Endoscopic Follow-up. Intern Med, 55:3585-3590, 2016

158.Hatake K, Doi T, Uetake H, Takahashi Y, Ishihara Y, Shirao K. Bevacizumab safety in Japanese patients with colorectal cancer. Jpn J Clin Oncol, 46:234-240, 2016

159.Sawada T, Araki J, Yamashita T, Masubuchi M, Chiyoda T, Yunokawa M, Hoshi K, Tao S, Yamamura S, Yatsushiro S, Abe K, Kataoka M, Shimoyama T, Maeda Y, Kuroi K, Tamura K, Sawazumi T, Minami H, Suda Y, Koizumi F. Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer. EBioMedicine, 11:173-182, 2016

160.Yonemori K, Hirakawa A, Kawachi A, Kinoshita F, Okuma H, Nishikawa T, Tamura K, Fujiwara Y, Takebe N. Drug induced interstitial lung disease in oncology phase I trials. Cancer Sci, 107:1830-1836, 2016

161.Nishida T, Doi T. Pazopanib for both GIST and soft-tissue sarcoma. Lancet Oncol, 17:549-550, 2016

162.Setsu N, Miyake M, Wakai S, Nakatani F, Kobayashi E, Chuman H, Hiraoka N, Kawai A, Yoshida A. Primary Retroperitoneal Myxoid Liposarcomas. Am J Surg Pathol, 40:1286-1290, 2016

163.Yonemori K, Tamura K, Kodaira M, Fujikawa K, Sagawa T, Esaki T, Shirakawa T, Hirai F, Yokoi Y, Kawata T, Hatano B, Takahashi Y. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol, 78:525-531, 2016

164.Yoshino T, Kojima T, Bando H, Yamazaki T, Naito Y, Mukai H, Fuse N, Goto K, Ito Y, Doi T, Ohtsu A. Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. Cancer Sci, 107:659-665, 2016

165.Shibata H, Kato S, Sekine I, Abe K, Araki N, Iguchi H, Izumi T, Inaba Y, Osaka I, Kawai A, Kinuya S, Kodaira M, Kobayashi E, Kobayashi T, Sato J, Shinohara N, Takahashi S, Takamatsu Y, Takayama K, Tateishi U, Nagakura H, Hosaka M, Morioka H, Moriya T, Yuasa T, Yurikusa T, Yomiya K, Yoshida M. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open, 1:e000037, 2016

166.Zenke Y, Umemura S, Motegi A, Furukawa K, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Akimoto T, Goto K. Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non-Small Cell Lung Cancer. J Thorac Oncol, 11:1181-1183, 2016

167.Sofue K, Takeuchi Y, Tsurusaki M, Shibamoto K, Sakamoto N, Kitajima K, Sone M, Sugimura K, Arai Y. Value of Percutaneous Radiologic Gastrostomy for Patients with Advanced Esophageal Cancer. Ann Surg Oncol, 23:3623-3631, 2016

168.Sone M, Arai Y, Sugawara S, Tomita K, Fujiwara K, Ishii H, Morita S. Angio-CT-Assisted Balloon Dissection: Protection of the Adjacent Intestine during Cryoablation for Patients with Renal Cancer. J Vasc Interv Radiol, 27:1414-1419, 2016

169.Takahashi K, Morota M, Kagami Y, Okamoto H, Sekii S, Inaba K, Murakami N, Igaki H, Ito Y, Uno T, Itami J. Prospective study of postoperative whole breast radiotherapy for Japanese large-breasted women: a clinical and dosimetric comparisons between supine and prone positions and a dose measurement using a breast phantom. BMC Cancer, 16:757, 2016

170.Mukai H, Saeki T, Aogi K, Naito Y, Matsubara N, Shigekawa T, Ueda S, Takashima S, Hara F, Yamashita T, Ohwada S, Sasaki Y. Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. Cancer Sci, 107:1465-1470, 2016

171.Takahashi K, Yoshida H, Watanabe R, Ishikawa M, Ikeda SI, Kato T. Metastasis of extra-ampullary duodenal adenocarcinoma to the uterine cervix. Malays J Pathol, 38:45-48, 2016

172.Takaoka Md M, Okuyama A, Mekata E, Masuda M, Otani M, Higashide S, Higashi T. Staging discrepancies between Hospital-Based Cancer Registry and Diagnosis Procedure Combination data. Jpn J Clin Oncol, 46:788-791, 2016

173.Takeuchi A, Tsuchiya H, Ishii T, Nishida Y, Abe S, Matsumine A, Kawai A, Yoshimura K, Ueda T. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study. BMC Musculoskelet Disord, 17:306, 2016

174.Tanaka R, Sasajima Y, Tsuda H, Namikawa K, Takahashi A, Tsutsumida A, Fujisawa Y, Fujimoto M, Yamazaki N. Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease. Clin Exp Metastasis, 33:687-697, 2016

175.Mukai H, Higashi T, Sasaki M, Sobue T. Quality evaluation of medical care for breast cancer in Japan. Int J Qual Health Care, 28:110-113, 2016

176.Tsutsumida A, Takahashi A, Namikawa K, Yamazaki N, Uhara H, Teramoto Y, Takenouchi T, Fukushima S, Yokota K, Uehara J, Matsushita S, Shibayama Y, Hatta N, Masui Y, Uchi H, Fujisawa Y, Ogata D. Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan. Int J Clin Oncol, 21:796-800, 2016

177.Tsukada Y, Nakamura F, Iwamoto M, Terahara A, Higashi T. Patterns of prescribing radiotherapy and bevacizumab in nationwide practice - analysis of 101 designated cancer care hospitals in Japan. J Radiat Res, 57:157-163, 2016

178.Zenda S, Ota Y, Tachibana H, Ogawa H, Ishii S, Hashiguchi C, Akimoto T, Ohe Y, Uchitomi Y. A prospective picture collection study for a grading atlas of radiation dermatitis for clinical trials in head-and-neck cancer patients. J Radiat Res, 57:301-306, 2016

179.Yamazaki N, Uhara H, Wada H, Matsuda K, Yamamoto K, Shimamoto T, Kiyohara Y. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma. J Dermatol, 43:1146-1153, 2016

180.Yamazaki T, Enokida T, Wakasugi T, Zenda S, Motegi A, Arahira S, Akimoto T, Tahara M. Impact of prophylactic percutaneous endoscopic gastrostomy tube placement on treatment tolerance in head and neck cancer patients treated with cetuximab plus radiation. Jpn J Clin Oncol, 46:825-831, 2016

181.Iwamoto M, Nakamura F, Higashi T. Monitoring and evaluating the quality of cancer care in Japan using administrative claims data. Cancer Sci, 107:68-75, 2016

182.Tokuda T, Arai Y, Sone M, Sugawara S, Morita S, Saito Y. Coil Embolization for the Treatment of Esophageal Perforation after Endoscopic Submucosal Dissection. J Vasc Interv Radiol, 27:1461-1463, 2016

183.Zenda S, Akimoto T, Mizumoto M, Hayashi R, Arahira S, Okumura T, Sakurai H. Phase II study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinuses. Radiother Oncol, 118:267-271, 2016

184.Motegi A, Fujii S, Zenda S, Arahira S, Tahara M, Hayashi R, Akimoto T. Impact of Expression of CD44, a Cancer Stem Cell Marker, on the Treatment Outcomes of Intensity Modulated Radiation Therapy in Patients With Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys, 94:461-468, 2016

185.Honma Y, Yamada Y, Terazawa T, Takashima A, Iwasa S, Kato K, Hamaguchi T, Shimada Y, Ohashi M, Morita S, Fukagawa T, Machida N, Katai H. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma. Surg Today, 46:1076-1082, 2016

186.Hatogai K, Yano T, Kojima T, Onozawa M, Fujii S, Daiko H, Yoda Y, Hombu T, Doi T, Kaneko K, Ohtsu A. Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer. Radiat Oncol, 11:31, 2016

187.Hatogai K, Fujii S, Kojima T, Daiko H, Kadota T, Fujita T, Yoshino T, Doi T, Takiguchi Y, Ohtsu A. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. J Surg Oncol, 113:390-396, 2016

188.Inaba K, Nakamura S, Okamoto H, Kashihara T, Kobayashi K, Harada K, Kitaguchi M, Sekii S, Takahashi K, Murakami N, Ito Y, Igaki H, Uno T, Itami J. Early-onset dropped head syndrome after radiotherapy for head and neck cancer: dose constraints for neck extensor muscles. J Radiat Res, 57:169-173, 2016

189.Hatogai K, Yano T, Kojima T, Onozawa M, Daiko H, Nomura S, Yoda Y, Doi T, Kaneko K, Ohtsu A. Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Gastrointest Endosc, 83:1130-1139 e1133, 2016

190.Kubota D, Kosaka N, Fujiwara T, Yoshida A, Arai Y, Qiao Z, Takeshita F, Ochiya T, Kawai A, Kondo T. miR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma. Sarcoma, 2016:1390571, 2016

191.Sakuyama N, Kojima M, Kawano S, Akimoto T, Saito N, Ito M, Ochiai A. Histological differences between preoperative chemoradiotherapy and chemotherapy for rectal cancer: a clinicopathological study. Pathol Int, 66:273-280, 2016

192.Kotani D, Shitara K, Kawazoe A, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. Clin Colorectal Cancer, 15:e109-115, 2016